Trial Profile
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Cediranib (Primary) ; Olaparib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Male breast cancer; Non-small cell lung cancer; Pancreatic cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer
- Focus Therapeutic Use
- 11 Apr 2024 Planned End Date changed from 31 Dec 2023 to 10 Apr 2025.
- 11 Apr 2024 Status changed from discontinued to active, no longer recruiting.
- 27 Mar 2024 Status changed from active, no longer recruiting to discontinued, due to Inadequate accrual rate.